Luke joined Consilient Health in 2005 in a non-executive capacity before taking up the role of Executive Vice Chairman. He was appointed as Chief Executive in May 2022.

Before taking up his role at Consilient Health, Luke had over 20 years’ experience working in Private Equity. This included time spent at Hibernia Capital Partners and Allen McGuire & Partners in Dublin advising on investment and transactions with companies operating in a variety of industries in the UK, Sweden, France and the US.

John joined Consilient Health as Finance Director in October 2020.

Prior to taking up his role at Consilient Health, John held a number of senior finance positions including Chief Financial Officer & Company Secretary of TVC Holdings plc, a publicly quoted investment holding company. He was formerly the Group Financial Controller & Company Secretary of Tedcastle Holdings, an Irish industrial holding company. John has significant experience in both operating and strategic finance roles, including fundraising on public and private markets.

John holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of Chartered Accountants Ireland.

Shane is the Non-Executive Chairman of Consilient Health and his family investment vehicle is the majority shareholder in the Company.

Shane founded two private equity/venture capital businesses based in Ireland, as well as formerly being the joint CEO of Tedcastle Holdings, a significant Irish private business which retails and distributes oil and petroleum products. He has chaired several publicly listed and private companies and worked for a number of years at Dillon Read Investment bank in New York prior to returning to Ireland.

Shane holds an MBA from Colombia Business School.

With over 25 years in the industry, Harald has extensive international board and operational experience with therapeutics, diagnostics and medical devices.

Before being appointed as a Non-Executive Director of Consilient Health in 2018, Harald’s previous roles included President and CEO of OvaScience, President and CEO of ArjoHuntleigh AB, CEO of Grünenthal, and Chair and Managing Director at DePuy International. Harald currently also is the Executive Chair of Eptiva Therapeutics Ltd. and Domus Diagnostics, Inc., and a Non-Executive Director at CognifiSense, Inc., and Rentschler Biopharma SE, spanning the US, UK, and Germany.

Consilient Health benefit from Harald’s extensive international experience, including Europe and the US, in a broad range of company sizes and therapeutic areas. Harald holds degrees in Chemistry, with a PhD in Inorganic Chemistry from Heidelberg University in 1997.

With over 40 years’ experience in the pharmaceutical industry, John is perhaps best known for launching Boehringer Ingelheim’s first blockbuster brand, Spiriva (for COPD: chronic obstructive pulmonary disease), which achieved peak sales of more than €5 billion.

John first joined the pharmaceutical industry as a Medical Representative in 1974 and in 1982 he joined Boehringer Ingelheim. Having built Spiriva as Head of Global Marketing he became Managing Director for Australia and New Zealand before returning to the UK as Managing Director for the UK and Ireland. After a successful 31 year career with Boehringer Ingelheim John retired from the company at the end of 2013.

John holds a Natural Sciences Degree from Cambridge University and a Masters in Space Physics from Leicester University.

Blanca joined Consilient Health in September 2020 as New Business Development Manager and was promoted to Head of Business Development in January 2023.

With 18 years of experience in the pharmaceutical industry, she leads the Business Development Team and drives the expansion of Consilient Health’s product pipeline through strategic in-licensing and acquisition activities across all operating regions.

Over the course of her career, Blanca has held IP roles at Laboratorios Salvat and Sandoz, as well as leadership positions in portfolio management and business development at Britannia Pharmaceuticals, Chanelle Medical, and Advanz Pharma.

Blanca holds an MSc in Chemistry from the University of Barcelona and an MBA from Hult International Business School.

Anaïs joined Consilient Health in June 2024 as Business Development Manager. In her role, she identifies, secures and delivers new business opportunities to enhance the Consilient Health product portfolio as well as supporting the long-term business strategy and ensuring profitable growth.

Anaïs has been working in the pharmaceutical industry for over 12 years in different roles and geographies. She initially held consultancy roles within the manufacturing & supply field for Pfizer, GSK and UCB and then she moved to Norgine where she spent 10 years in various Business Development & Licensing roles. Most recently she worked at Advanz Pharma before joining Consilient Health.

Anaïs has an MSc in Process Engineering from the IMT Mines Albi (France).

Neha joined Consilient Health’s Business Development team in July 2021 as Business Development Portfolio Coordinator and was promoted to Business Development Executive in April 2024, her key responsibilities include identifying new product opportunities for in-licensing, expanding our portfolio of partners, and delivering new product opportunities to strengthen the company’s portfolio. Neha also plays a critical role in tracking patent landscapes and monitoring competitor landscape activity.

Before joining Consilient Health, Neha’s previous roles include working for IQVIA in primary market research and for GSK within Regulatory Affairs. Most recently, and for 11 years, Neha has been working in Business Development for Advanz Pharma. Her most recent position was Senior Portfolio Executive where her focus has been Portfolio Management including supporting the identification, managing, and tracking of pipeline products for the global BD teams to help drive and deliver successful pipeline launches.

Neha holds an HND in Applied Biology from University of Hertfordshire.

Kirsty Andrews joined Consilient in August 2023 as part of the Business Development team. With over a decade of experience in the pharmaceutical industry, Kirsty has developed extensive knowledge through her work in Business Development (BD) and Account Management (ACM) for Contract Manufacturing Organizations (CMOs) and distributors.

In her role, Kirsty is focused on identifying opportunities to in-license, partner with, or potentially acquire developed, market-ready products for both the generic and branded portfolios across all our operating regions.

Blanca joined Consilient Health in September 2020 as New Business Development Manager and was promoted to Head of Business Development in January 2023.

With 18 years of experience in the pharmaceutical industry, she leads the Business Development Team and drives the expansion of Consilient Health’s product pipeline through strategic in-licensing and acquisition activities across all operating regions.

Over the course of her career, Blanca has held IP roles at Laboratorios Salvat and Sandoz, as well as leadership positions in portfolio management and business development at Britannia Pharmaceuticals, Chanelle Medical, and Advanz Pharma.

Blanca holds an MSc in Chemistry from the University of Barcelona and an MBA from Hult International Business School.

Anaïs joined Consilient Health in June 2024 as Business Development Manager. In her role, she identifies, secures and delivers new business opportunities to enhance the Consilient Health product portfolio as well as supporting the long-term business strategy and ensuring profitable growth.

Anaïs has been working in the pharmaceutical industry for over 12 years in different roles and geographies. She initially held consultancy roles within the manufacturing & supply field for Pfizer, GSK and UCB and then she moved to Norgine where she spent 10 years in various Business Development & Licensing roles. Most recently she worked at Advanz Pharma before joining Consilient Health.

Anaïs has an MSc in Process Engineering from the IMT Mines Albi (France).

Neha joined Consilient Health’s Business Development team in July 2021 as Business Development Portfolio Coordinator and was promoted to Business Development Executive in April 2024, her key responsibilities include identifying new product opportunities for in-licensing, expanding our portfolio of partners, and delivering new product opportunities to strengthen the company’s portfolio. Neha also plays a critical role in tracking patent landscapes and monitoring competitor landscape activity.

Before joining Consilient Health, Neha’s previous roles include working for IQVIA in primary market research and for GSK within Regulatory Affairs. Most recently, and for 11 years, Neha has been working in Business Development for Advanz Pharma. Her most recent position was Senior Portfolio Executive where her focus has been Portfolio Management including supporting the identification, managing, and tracking of pipeline products for the global BD teams to help drive and deliver successful pipeline launches.

Neha holds an HND in Applied Biology from University of Hertfordshire.

Kirsty Andrews joined Consilient in August 2023 as part of the Business Development team. With over a decade of experience in the pharmaceutical industry, Kirsty has developed extensive knowledge through her work in Business Development (BD) and Account Management (ACM) for Contract Manufacturing Organizations (CMOs) and distributors.

In her role, Kirsty is focused on identifying opportunities to in-license, partner with, or potentially acquire developed, market-ready products for both the generic and branded portfolios across all our operating regions.

Blanca joined Consilient Health in September 2020 as New Business Development Manager and was promoted to Head of Business Development in January 2023.

With 18 years of experience in the pharmaceutical industry, she leads the Business Development Team and drives the expansion of Consilient Health’s product pipeline through strategic in-licensing and acquisition activities across all operating regions.

Over the course of her career, Blanca has held IP roles at Laboratorios Salvat and Sandoz, as well as leadership positions in portfolio management and business development at Britannia Pharmaceuticals, Chanelle Medical, and Advanz Pharma.

Blanca holds an MSc in Chemistry from the University of Barcelona and an MBA from Hult International Business School.

Anaïs joined Consilient Health in June 2024 as Business Development Manager. In her role, she identifies, secures and delivers new business opportunities to enhance the Consilient Health product portfolio as well as supporting the long-term business strategy and ensuring profitable growth.

Anaïs has been working in the pharmaceutical industry for over 12 years in different roles and geographies. She initially held consultancy roles within the manufacturing & supply field for Pfizer, GSK and UCB and then she moved to Norgine where she spent 10 years in various Business Development & Licensing roles. Most recently she worked at Advanz Pharma before joining Consilient Health.

Anaïs has an MSc in Process Engineering from the IMT Mines Albi (France).

Neha joined Consilient Health’s Business Development team in July 2021 as Business Development Portfolio Coordinator and was promoted to Business Development Executive in April 2024, her key responsibilities include identifying new product opportunities for in-licensing, expanding our portfolio of partners, and delivering new product opportunities to strengthen the company’s portfolio. Neha also plays a critical role in tracking patent landscapes and monitoring competitor landscape activity.

Before joining Consilient Health, Neha’s previous roles include working for IQVIA in primary market research and for GSK within Regulatory Affairs. Most recently, and for 11 years, Neha has been working in Business Development for Advanz Pharma. Her most recent position was Senior Portfolio Executive where her focus has been Portfolio Management including supporting the identification, managing, and tracking of pipeline products for the global BD teams to help drive and deliver successful pipeline launches.

Neha holds an HND in Applied Biology from University of Hertfordshire.

Kirsty Andrews joined Consilient in August 2023 as part of the Business Development team. With over a decade of experience in the pharmaceutical industry, Kirsty has developed extensive knowledge through her work in Business Development (BD) and Account Management (ACM) for Contract Manufacturing Organizations (CMOs) and distributors.

In her role, Kirsty is focused on identifying opportunities to in-license, partner with, or potentially acquire developed, market-ready products for both the generic and branded portfolios across all our operating regions.

Luke joined Consilient Health in 2005 in a non-executive capacity before taking up the role of Executive Vice Chairman. He was appointed as Chief Executive in May 2022.

Before taking up his role at Consilient Health, Luke had over 20 years’ experience working in Private Equity. This included time spent at Hibernia Capital Partners and Allen McGuire & Partners in Dublin advising on investment and transactions with companies operating in a variety of industries in the UK, Sweden, France and the US.

Dr Roger Wu has over 20 years’ experience in the pharmaceuticals industry and was appointed as Chief Operating Officer of Consilient Health in January 2020. He is responsible for leading the overall operational needs of the company and delivering the business strategy through Supply Chain, Quality Assurance, Regulatory Affairs and Technical Projects.

Prior to joining Consilient Health, Roger led many teams across multiple disciplines, including product development and project management in large pharmaceutical companies such as GSK and technical operations in generic pharmaceutical companies such as AMCo (now Advanz Pharma).

Roger holds a PhD from University of East Anglia in Pharmaceutical Sciences and an Executive MBA from Imperial College London.

John joined Consilient Health as Finance Director in October 2020.

Prior to taking up his role at Consilient Health, John held a number of senior finance positions including Chief Financial Officer & Company Secretary of TVC Holdings plc, a publicly quoted investment holding company. He was formerly the Group Financial Controller & Company Secretary of Tedcastle Holdings, an Irish industrial holding company. John has significant experience in both operating and strategic finance roles, including fundraising on public and private markets.

John holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of Chartered Accountants Ireland.

Anne has more than 25 years industry experience. She joined Consilient Health in 2015 and is responsible for leading and delivering the overall medical resource for the Company. This includes ensuring compliance with all relevant regulations and Codes of Practice and that Patient Centricity is at the forefront of all Consilient Health’s activities. As a member of the Pharma Business Development team, Anne assesses potential new product acquisitions.

Anne qualified in medicine and spent seven years working full time and five years part time in the NHS, specialising in Medical Oncology. Anne has broad industry medical experience across many therapeutic areas and responsibilities have included leadership and direction of UK and Irish medical departments at Sanofi-Synthelabo, Novartis and Ipsen, medical consultancy to the industry for nearly 10 years, and a non-Executive Directorship at Biocompatibles.

Anne has a medical degree from Southampton University and is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine.

Learn more about Anne’s role in the Business Development team in the video below:

Since joining Consilient Health in 2017, Amanda has led the launch and commercialisation of medicines across primary and secondary care environments, from widely prescribed treatments to therapies for rare diseases. She and her team work closely with healthcare professionals and payors to ensure patients have access to innovative and effective medicines.

Previously, Amanda spent 20 years at Boehringer Ingelheim, advancing from managerial roles in Sales, Marketing, and Training to Director-level positions in Sales, Strategy, and Business Development. She has also consulted within the pharmaceutical industry, specializing in business and marketing excellence across Europe and internationally. Additionally, Amanda served as a Non-Executive Director at Datapharm, a leading source of medicines information.

Amanda holds qualifications in management, digital marketing, and leadership development from institutions including the Chartered Institute of Marketing, ILM, and Duke University.

Mark has over 30 years industry experience. He joined Consilient Health in 2008 as its first National Accounts Manager. Mark has built Consilient Health’s generics business in large retail chains and national wholesalers for over ten years. He looks after international export opportunities on generics and branded business.

Prior to Consilient Health, Mark worked at Sandoz for 12 years, firstly as a Regional Manager for its generics team, progressing to the role of National Account Manager and then managing their National Account Team. Before Sandoz, Mark worked for seven years, firstly at Lipha Pharmaceuticals and then at Lorex Synthelabo in their branded Sales Divisions.

Mark holds a BSc (Hons) from West London Institute of Higher Education in Sports Studies and Geography in addition to a PGCE from Loughborough University.

Henrik joined Consilient Health in 2016 and is responsible for the Nordic operations which includes Sweden, Norway, Denmark and Finland. He manages the Nordic Sales & Marketing team and contributes to business development in the region. His role is to ensure that Consilient Health collaborates with both healthcare professionals and partners to identify unmet medical needs and that patients receive optimal medical therapies.

Henrik started his career in Swedish Healthcare as a registered Nurse before he moved to the Pharmaceutical industry in 1995. Prior to joining Consilient Health Henrik worked in different sales & marketing positions for various pharmaceutical companies including Glaxo Wellcome, Pharmacia and Pfizer. He gained experience from international projects within WHO Collaborating Centre for International Drug Monitoring and as Nordic Marketing Manager at Renapharma.

Henrik has a BSc in Nursing from Uppsala University.

Deirdre joined Consilient Health in 2014 to set up the Irish business unit. Since then, Deirdre and the Irish team have successfully launched a range of medicines in both the secondary and primary care settings with new launches in Malta from 2021.

Prior to joining Consilient Health, Deirdre spent 13 years at Eli Lilly, most recently as business unit manager responsible for the Osteoporosis, Cardiology, Oncology and Primary Care product portfolios. At Novo Nordisk, she was the lead marketer for growth hormone in the UK & Ireland territories. Deirdre started her career at Nutricia where she held a number of management positions.

Deirdre has a BSc (Hons) in Nutrition & Dietetics from Trinity College, Dublin with post graduate qualifications in marketing, health economics and a Diploma from the Institute Of Directors. Deirdre is also the vice chair and board member of Medicines For Ireland trade association and a past president of the Irish Pharmaceutical Managers Institute (2022 / 2023).

Blanca joined Consilient Health in September 2020 as New Business Development Manager and was promoted to Head of Business Development in January 2023.

With 18 years of experience in the pharmaceutical industry, she leads the Business Development Team and drives the expansion of Consilient Health’s product pipeline through strategic in-licensing and acquisition activities across all operating regions.

Over the course of her career, Blanca has held IP roles at Laboratorios Salvat and Sandoz, as well as leadership positions in portfolio management and business development at Britannia Pharmaceuticals, Chanelle Medical, and Advanz Pharma.

Blanca holds an MSc in Chemistry from the University of Barcelona and an MBA from Hult International Business School.

Ian has worked within the pharmaceutical industry for over 35 years and joined Consilient Health in 2015. As Head of Supply Chain he is responsible for product delivery through Customer Services, and Supply Chain, where functions include management of global CMO’s. Ian works as a member of the senior management team to build and improve the company product Supply Chain structures to support the current product portfolio and continued growth in an expanding company.

Ian has worked in the pharmaceutical industry since 1984, with over 30 of these years being directly associated to the manufacturing environment.

He gained extensive experience in Quality Control and Quality Assurance with Roussel Laboratories before transferring his skills to Supply Chain and Demand Management with HMR. Most recently, Ian worked in Operational Excellence and Technical Business Management with Patheon UK Ltd.

Ian holds a HND Chemistry from the University West of England and an Auditor and Pharmaceutical Lead Assessor Accreditation from the British Standards Institute.

Jasdeep joined Consilient Health in January 2021 as the Head of Quality. The role is to develop the Quality service across the company sites and to support the introduction of new products.

He has experience over a large range of product types and has a keen interest in the end user perspective.

Jasdeep qualified as a Pharmacist in the UK 1999 and the held various Pharmaceutical Manufacturing and Quality roles in the NHS and has acted as a transitional QP since 2004. He has managed two London based manufacturing units and introduced commercialised product portfolios with particular interest in new products and clinical trials. He is a KOL with respects to automated aseptic manufacturing of intravenous nutrition based and ready to administer products. He developed a national program to facilitate the use of new technologies. From 2011-2020 he was involved at the strategic development all the NHS manufacturing units as part of national improvement program working closely with NHSI and DHSC.

In February 2020 he completed his MBA with Imperial Business School in the UK.